Ofir Frenkel, n/a

Novo Nordisk A/S,
Søborg, Denmark, Denmark

Poster(s):

• (P178) SEMAGLUTIDE AND CARDIOVASCULAR OUTCOMES IN PEOPLE WITH OVERWEIGHT OR OBESITY AND HEART FAILURE: A PRE-SPECIFIED ANALYSIS FROM THE SELECT TRIAL
  Saturday, October 26, 2024

  1:30 PM – 2:00 PM PT